Health Care/Hospital
BRIDGING CLINICAL RESEARCH AND CLINICAL CARE WITH AI-AIDING PATHOLOGISTS TOOL
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- A newly published collaborative study
2024-12-09 12:40
1335
Reimagining our urban futures: Health-Driven Design for Cities (HD4) research programme launches in Singapore
SINGAPORE, Dec. 9, 2024 /PRNewswire/ -- December sees the launch of Health-Driven Design for Cities (HD4), a groundbreaking Singapore-based research collaboration seeking to discover how best to design urban environments that enhance the health of their residents. HD4 is a partnership betwe...
2024-12-09 12:12
1294
2024 ASH Oral Presentation----Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting
SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients with chronic Graft-versus-Host Disease (cGvHD) who have either progressed or not responded to one or mo...
2024-12-09 10:40
1176
Survey Finds 80% of Parents Concerned About Academic Pressure, Silence Booths as an Innovative Solution to Campus Space Challenges
HONG KONG, Dec. 9, 2024 /PRNewswire/ -- Learning environments significantly impact students' focus and mental well-being. However, limited living space in Hong Kong has exacerbated challenges in providing adequate study areas. A recent "Learning Environment Survey" conducted by ESDlife from Octobe...
2024-12-09 10:00
1316
Jacobio Pharma Presented preliminary Data on BET Inhibitor for Myelofibrosis at 2024 ASH
BEIJING, SHANGHAI and BOSTON, Dec. 8, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat myelofibrosis (MF) at the 2024 ASH (Ame...
2024-12-09 08:42
1020
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...
2024-12-09 08:20
1567
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-12-09 08:00
1788
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
Day 3 explored the philosophical contributions to the quality of life, and the ethical implications of AI and its impact on human life RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ -- The Riyadh International Philosophy Conference 2024 concluded its third and final day with a series of thought...
2024-12-08 22:18
1356
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This year, EpiVax expanded the b...
2024-12-07 11:30
3458
Caliway Biopharmaceuticals Included in FTSE TWSE Taiwan Eight Industries and Mid-Cap 100 Indices
NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is proud to announce its inclusion in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index, two prestigious benchmarks jointly compiled by FTSE Russell and the Taiwan S...
2024-12-07 08:57
3204
Qi Biodesign Completes $75 Million in Total Funding to Drive Genome Editing Innovations
BEIJING, Dec. 6, 2024 /PRNewswire/ -- Qi Biodesign, a biotechnology company pioneering next-generation genome editing technologies, announced the completion of its Series A funding round. The company has now raised a total of $75 million across its Seed, Series Pre-A, and Series A stages. The Seri...
2024-12-06 20:15
6701
Another star technology platform of the Sanyou AI-STAL family
——Introducing Sanyou Mrna Mab innovative antibody generation technology platform SHANGHAI, Dec. 6, 2024 /PRNewswire/ -- With the announcement of the 2024 Nobel Prize in Physiology or Medicine, microRNA has once again become the focus of global attention. In the past 20 years, three Nobel Prizes h...
2024-12-06 18:30
1568
Empowering Lives, One Act of Kindness at a Time
Flood Relief for 147 Families in Need KUALA LUMPUR, Malaysia, Dec. 6, 2024 /PRNewswire/ -- Though the rain may have been relentless, USANA Foundation has once again proven that the power of community-driven initiatives can bring real, lasting change. Our commitment to standing by those in need h...
2024-12-06 18:00
1626
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event inSingapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, thi...
2024-12-06 10:41
7125
SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center
* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...
2024-12-06 09:00
1970
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...
2024-12-06 08:07
1773
VISTA Eye Specialist Partners with PX Movement to Revolutionize Eye Care
PETALING JAYA, Malaysia, Dec. 6, 2024 /PRNewswire/ -- VISTA Eye Specialist (VISTA), Malaysia's leading provider of comprehensive eye care and refractive surgery services, proudly announces a transformative partnership with thePX Ninety program, led by world-renowned patient experience expert Shar...
2024-12-06 08:00
1588
Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
OSAKA, Japan and MONTREAL , Dec. 5, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka, Japan; President: Toichi Takino; "Ono") announced that it has entered into a drug discovery collaboration agreement with Congruence Therapeutics (Headquarters:Montreal, Quebec, Canada; CEO:...
2024-12-06 07:56
1245
USANA Malaysia Named the Top Combination Dietary Supplements and Calcium Supplements Brand by Euromonitor International
KUALA LUMPUR, Malaysia, Dec. 6, 2024 /PRNewswire/ -- USANA Malaysia was recently awarded the title Top #1 Combination Dietary and Calcium Supplements Brand inMalaysia by market research giant Euromonitor International. This marks the sixth consecutive year the market received the combination diet...
2024-12-06 07:52
1484
KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024
SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the
covetedRaw Material Supplier of the Year Award 2024 at the Complementary
Medicines Australia (CMA) Awards, held inSydney this evening.
2024-12-06 06:10
1953
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 309 media titles]
2024-12-19 17:56
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 263 media titles]
2024-12-23 17:36
Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
10186
Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
2024-12-19 17:56
9803
